Join to access to all OVN content. Join for Free
Perceived, Probe, Reflect-KOL Engagement Model
KOL engagement model MSL role evolution pre-call planning strategies effective probing techniques common MSL mistakes

Perceived, Probe, Reflect-KOL Engagement Model


Share This Article


Summary

In this episode, Tom Caravela is joined by Cto delve into her innovative KOL engagement model. Amy shares her career journey and introduces her perceive, probe, and reflect approach. The discussion covers the importance of pre-call planning, researching KOLs, and adapting to various personality types. Amy provides insights into effective probing techniques, setting up future engagements, and follow-up strategies. The conversation also addresses common mistakes made by MSLs and offers advice for overcoming challenges. The episode concludes with thoughts on the future of the MSL role and a reminder for listeners to subscribe and leave reviews.

My guest today is Amy Patel, Executive Medical Scientific Liaison, with Takeda Pharmaceuticals and she shares her KOL Engagement Model…Perceived, Probe, Reflect

Amy discusses…

👉 How she came up with “Perceived, Probe, Reflect”
👉 The importance of pre-calling plans for MSLs
👉 How MSLs should conduct research on their KOLs
👉 Her advice for MSLs on probing
👉 What MSLs need to take out of KOL meetings
👉 Recommendations for follow-ups
👉 Common mistakes with KOL engagement

Click for Source
KOL engagement model, MSL role evolution, pre-call planning strategies, effective probing techniques, common MSL mistakes

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
The Future MSL
Partner Avatar MSL Talk: Tom Caravela, Eddie Power

The Future MSL

Podcast
The MSL - 4 Years, 200 Episodes…What’s new, What’s not
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The MSL - 4 Years, 200 Episodes…What’s new, What’s not

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Explore OVN